Emily Menendez

DocwireNews

While phase I trials can provide access to new therapies and treatments, the benefits of these trials in patients with unresectable upper gastrointestinal (UGI) cancers remain unclear due to limited treatment options and poor prognosis of the disease.
A recent analysis has utilized data from the <a href="https://journals.sagepub.com/doi/10.1177/17588359251318864" target="_blank" rel="noopener">Sarah Cannon Research Institute UK Drug Development Unit</a> to determine the efficacy and survival outcomes of patients with advanced refractory UGI cancers involved in phase I studies.
A total of 124 patients with UGI cancers were included in 37 phase I trials and received at least one dose of a study drug from 2011 to 2023. Outcomes assessed included objective response rate (ORR), clinical benefit rate (CBR), disease control rate (DCR), duration of response, progression-free survival (PFS), and overall survival (OS).
Analyses were conducted across the entire cohort and stratified by trial agent class, molecularly matched therapy assignment, and receipt of the recommended phase II dose (RP2D). Patients enrolled in multiple trials were evaluated independently for each study.
Most patients (73%) had liver or peritoneal metastases, which were treated with a median of two prior lines of therapy. Of these patients, 60% underwent immunotherapy, 30% received small-molecule drugs, and 10% received antibody-drug conjugates.
A total of 22% of patients underwent molecularly matched therapy, while 86% received treatment at RP2D. The ORR was 15%, CBR 40%, DCR 86%, and median OS was 9.7 months in response-evaluable patients. Patients treated with RP2D had higher CBR (odds ratio 4.75, P=0.04) and prolonged PFS (P=0.04). Depth of response and treatment at RP2D served as independent prognostic factors.
Patients with refractory UGI cancers who participated in phase I trials saw benefits in late-line settings, along with potential early access to new therapies.

Laura Litwin

Novel Genetic Mutation Connected to Rare Case of Drug Resistance in Advanced NSCLC

Non-Small Cell Lung Cancer

Phase I Trials Benefit Patients With Upper Gastrointestinal Cancers

Gastroesophageal Cancer

Jordana Jampel

Tumor-Infiltrating Lymphocyte Analysis for Survival Outcomes in Early ERBB2-Positive Breast Cancer

Breast Cancer News

Latest News

A recent analysis has determined the efficacy and survival outcomes of patients with advanced refractory UGI cancers involved in phase I studies.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe